BMJ Open 2020;10:e033231.ArticlePubMedPMC 71
PGC1, peroxisome proliferator-activated receptor-gamma coactivator 1
Amino acids are the building blocks of protein, and they're essential for physical performance
between-group differences significant (ANOVA P=0.033), with post-hoc group1 (double placebo) vs group4 (double active) P=0.005
(Kailera), a clinical-stage biopharmaceutical company focused on advancing a differentiated, late-stage portfolio of next-generation therapies for the treatment of obesity, today announced the presentation of additional data from Hengruis Phase 3 clinical trial 1 (GEMINI-1) of a once-weekly subcutaneous injection of HRS9531, a novel dual GLP-1/GIP receptor agonist, in individuals living with obesity or overweight in China (NCT06396429) at ObesityWeek 2025, the annual meeting of The Obesity Society (TOS)
Modification of cysteine thiols of Keap1 and Nrf2 by inducers presumably alters the structure of the Nrf2/Keap1/Cul3 complex, leading to inhibition of Nrf2 ubiquitination ( Figure 2 c )
%20(1).png)
